Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Atopic dermatitis is long lasting (chronic) and tends to flare periodically and then subside. It may be accompanied by asthma or hay fever.
OMICS International, Organizes 1000+ Global Events, Every Year across USA, Europe & Asia with support from 1000 more scientific societies, and Publishes 700+ Open access journals, which contains over 1,00,000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series, website will provide you list and details about the conference organize worldwide.
Scope and Importance:
Disorders of the skin, hair, and nails fall within the remit of a dermatologist. The specialty is divided broadly into medical and surgical fields, with clinicians in secondary care often practising both. It should be noted that in some countries, training and practice in dermatology are combined with venerology. Dermatology is chiefly an outpatient specialty, and most patient referrals request an initial diagnosis and treatment of an unknown skin disease or review of more complex and chronic cases beyond the skill of the general practitioner. Many developing countries have no skin care specialists and referral is made difficult by distances and availability of travel funds. For example, South Africa has a ratio of 3 to 4 million people per dermatologist, who are usually located in urban areas.
21-87% of the population may be affected by some type of skin problem. Primary care providers are often unable to diagnose and treat skin disease; the economic burden of skin disease in the United States is large: approximately $35.9 billion.
Atopic dermatitis (AD) also known as atopic eczema or eczema is a type of dermatitis, an inflammatory, relapsing, non-contagious and itchy skin disorder. It has been given names like "prurigo Besnier," "neurodermatitis," "endogenous eczema," "flexural eczema," "infantile eczema," and "prurigo diathésique".
The cause of AD is not known, although there is some evidence of genetic factors, and some evidence that growing up in a sanitaryenvironment encourages AD. It seems to have a genetic component. Many people with AD have a family history of atopy. Atopy is an immediate-onset allergic reaction such as asthma, dermatitis. Most importantly two mutations were found that affect approximately 5% of people in Western Europe that may disrupt the production of filaggrin. Filaggrin is a protein that plays an important role in the retention of water in the stratum corneum. People who have these mutations often have dry dermatitis. There is also support from epidemiological studies for a protective role for helminths against AD. Likewise children with poor hygiene are at a lower risk for developing AD, as are children who drink unpasteurised milk. Exposure to dust mites are believed to contribute to one's risk of developing AD.
There is no known cure for AD, although treatments may reduce the severity and frequency of flares. Applying moisturisers may prevent the skin from drying out and decrease the need for other medications. Affected persons often report that improvement of skin hydration parallels with improvement in AD symptoms. Additionally topical corticosteroids, especially hydrocortisone have proven themselves effective in managing AD. If topical corticosteroids and moisturisers fail, short-term treatment with topical calcineurin inhibitors liketacrolimus or pimecrolimus may be tried, although they are usually avoided as they can cause skin cancer or lymphoma. Alternatively systemic immunosuppressants may be tried such as ciclosporin, methotrexate, interferon gamma-1b, mycophenolate mofetil andazathioprine.
The atopic dermatitis therapeutic sales in the nine major markets (9MM) - the US, France Germany, Italy, Spain, UK, Japan, China and India - are forecast to increase from $3.9 billion in 2012 to $5.6 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.8%, says research and consulting firm Global Data.
According to the company’s latest report, the anticipated launch of new drugs by Sanofi/Regeneron and Anacor in the mid-term of the forecast period will bring a major boost to the market. Japan will also play a key role in driving global sales, while emerging markets India and China will experience rapid uptake of topical calcineurin inhibitors. With an estimated drug-treated population that hovers around the 54 million mark over the next decade, opportunities will remain in this chronic dermatology disease for other drug developers with novel systemic therapies.
2) 6th Clinical Dermatology Conference
May 05-07, 2016 Chicago, USA
4) Pediatric Dermatology Conference
October 10-12, 2016 Manchester, UK
5) 11th Global Dermatologists Meeting
November 14-16, 2016, Dubai, UAE
6) Clinical Dermatology Congress
September 07-09, 2016 Sao Paulo, Brazil
7) Euro Dermatology Conference
June 13-15, 2016 Alicante, Spain
8) Skin Disease Education Foundation's 14th Annual Hawaii Dermatology Seminar
March 1-6, 2015 Hawaii, USA
9) Dermatology for Primary Care
June 22-26, 2015 FL, USA
10) Family Medicine: Dermatology Review
May 11-21, 2015 Barcelona, Spain
11) Dermatology for the PCP
January 31-Feb 06, 2015 FL, USA
12) Oral Dermatology and Pathology
June 14-21, 2015 Vancouver, Canada
13) World Conferences on Acne
14) ICDAM International Conference on Diet and Simple Skin
15) The American Consensus Conference on Acne
1) Sand Lake Dermatology Center
2) Agabang & Company
3) SkinKind Limited
4) Regeneron Pharmaceuticals, Inc.
5) Dermal Life
6) Dermatology Alliance, Patch Testing Centers of Excellence
7) Dermatology Associates of Concord
9) Johnson & Johnson
13) LEO Pharma
14) Apothecus Pharmaceutical Corp
15) Remedi Pharmaceuticals
16) Abgenix, Inc.
17) Abbott Laboratories
18) Acadia Pharmaceuticals
19) Active Pass Pharmaceuticals
20) Advanced Drug Delivery Technologies AG
This page will be updated regularly.
This page was last updated on November 27, 2022